The latest market report published by Credence Research, Inc. “Global Paroxysmal Nocturnal Hemoglobinuria Market By Treatment (Blood Transfusion, Medication and Stem Cell Transplant) – Growth, Future Prospects & Competitive Analysis, 2019 – 2027,” the global paroxysmal nocturnal hemoglobinuria is set to reach from US$ 2,341.4 Mn in 2018 to US$ 6,203.0 Mn by 2027 and is expected to expand at a CAGR of 11.7% from 2019 to 2027.
The hematopoietic stem cells originating from the bone marrow is said to undergo complications such as premature red blood cell hemolysis and formation of blood clots, which are the major clinical manifestation in paroxysmal nocturnal hemoglobinuria. The treatment approach for PNH is revolutionizing with approximately 16 drug molecules reported to be under clinical trial investigation and will have a positive impact on the PNH market growth during the forecast period.
Browse the full report Paroxysmal Nocturnal Hemoglobinuria Market – Growth, Future Prospects, Competitive Analysis, 2019 – 2027 report at https://www.credenceresearch.com/report/paroxysmal-nocturnal-hemoglobinuria-market
Paroxysmal nocturnal hemoglobinuria is an extremely rare disorder with a global incidence rate of 1.3 cases per 100,000 people, approximately 20,000 people worldwide are reported to be suffering with paroxysmal nocturnal hemoglobinuria. As per the research findings of International Bone Marrow Transplant Registry, hematopoietic stem cell transplantation from allogeneic donor is the only curative option for the treatment of severe paroxysmal nocturnal hemoglobinuria. However the high cost associated with this treatment protocol and high mortality rate has led to dampen the popularity of this treatment regimen as a viable option. Since its approval in 2007 Soliris (eculizumab) is the only licensed drug prescribed for the treatment of hemolysis associated with PNH. Excellent drug efficacy and safety reported during clinical trial investigation studies will increase the popularity of monoclonal antibodies as the most viable medication for the treatment of PNH.
North America with a share of 35% is the global leader in the regional segment for paroxysmal nocturnal hemoglobinuria market. As per the research findings of National Institute of Health (NIH) in the United States approximately 5,000 citizens are suffering with paroxysmal nocturnal hemoglobinuria. Affordable reimbursement scenario and domicile of key players such as Amgen, Inc., Alexion Pharmaceuticals, Roche, Regeneron Pharmaceuticals etc. together drive the market growth in North America region. In the second position is Europe representing 28% primarily due to high prevalence rate of paroxysmal nocturnal hemoglobinuria and supportive regulatory environment provided by European Medical Agency for the drug development used in PNH treatment. Asia Pacific holds 14.5% market share primarily due to rising public health awareness related to PNH treatment and developing healthcare infrastructure.
Pharmaceutcials giants competing to achieve a strong foothold in the paroxysmal nocturnal Hemoglobinuria market are Amgen, Inc., Achillion Pharmaceuticals, Alexion Pharmaceuticals, Inc., Akari Therapeutics, Apellis Pharmaceuticals, Inc., CinnaGen, F.Hoffman-La Roche Ltd., Novartis AG, Ra Pharmaceuticals and Regeneron Pharmaceutcials.
Download Free PDF Sample Request: https://www.credenceresearch.com/sample-request/59729
Key Market Movements:
- Rising prevalence of paroxysmal nocturnal hemoglobinuria (PNH) in patients above 40 years of age
- Orphan disease designation awarded by healthcare agencies worldwide to fast track novel drug development for its treatment
- Strong product pipeline with drug molecules under investigation in different stages to revolutionize treatment protocol for PNH
By Treatment (2017–2027; US$ Mn)
- Blood Transfusion
- Stem Cell Transplant
By Geography (2017–2027; US$ Mn)
- North America
- Latin America
- Middle East and Africa
Do Inquiry before buying for research report: https://www.credenceresearch.com/inquiry-before-buying/59729